Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy.

scientific article

Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy. is …
instance of (P31):
scholarly articleQ13442814
case reportQ2782326

External links are
P356DOI10.1155/2019/3901741
P932PMC publication ID6526544
P698PubMed publication ID31198610

P50authorEvangelos N LiberopoulosQ37830431
Eleni PapadokostakiQ64904771
P2860cites workHyperglycemic crises in adult patients with diabetesQ22241293
SGLT2 Inhibitors May Predispose to KetoacidosisQ28081173
Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitusQ30426632
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesQ34673134
Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical ProgramQ35973246
SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting SystemQ36370828
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patientsQ37524302
SGLT inhibitors in management of diabetesQ38195440
Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesQ38729780
Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature.Q38778239
Euglycemic Diabetic KetoacidosisQ38812956
SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and DiagnosisQ39047440
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trialQ47770648
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.Q50716118
Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor.Q50955035
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.Q51707689
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Q57026285
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE TrialsQ57026286
Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort studyQ59330606
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsQ61458485
Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 InhibitorsQ63071417
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSISQ63071443
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled TrialQ64129222
International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) InhibitorsQ64385669
Euglycaemic diabetic ketoacidosisQ67246133
Relationship between severity of hyperglycemia and metabolic acidosis in diabetic ketoacidosisQ70411990
Fracture Risk After Initiation of Use of Canagliflozin: A Cohort StudyQ90826991
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefitsQ91071787
Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesQ92980564
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P921main subjectdiabetic ketoacidosisQ877827
P304page(s)3901741
P577publication date2019-05-06
P1433published inCase reports in endocrinologyQ27724372
P1476titleEuglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy.
P478volume2019

Search more.